Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
about
First line vs delayed transplantation in myeloma: Certainties and controversiesMultiple myeloma in the very elderly patient: challenges and solutionsEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Reviews of individual patient data (IPD) are useful for geriatrics: an overview of available IPD reviews.Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.Multiple myeloma in the older adult: better prospects, more challenges.Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.Immunomodulatory drugs in multiple myeloma.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysisMultiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center reportEuropean perspective on multiple myeloma treatment strategies: update following recent congressesPreclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Update on risk stratification and treatment of newly diagnosed multiple myeloma.Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.Novel treatment paradigm for elderly patients with multiple myeloma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Thalidomide: features and potential significance in oral precancerous conditions and oral cancer.New Treatment Approaches for Older Adults with Multiple Myeloma.Sequential or combination therapy for multiple myeloma.
P2860
Q26745957-C75C81A0-AA69-47DB-921F-33630A916B8FQ26752991-9E8B0476-7F11-4E40-A032-8CCB959091B0Q26767418-E80FFC94-EC4F-4FFD-8A92-84DD966671E4Q26998884-AE06BDC0-9AEF-42BA-A401-70F6AA8EDE97Q27002668-776BC372-465A-4402-B765-333FDF7C4DB2Q30595175-FBB0E1FA-7A19-46D3-A6D1-9B4C08035508Q30650394-8F7A4E11-5B99-4F20-B070-92BC05B5DEB0Q30815345-E8C7544E-6547-4833-8EC2-CA81881EE0C9Q33400424-B5CD8B58-831A-40D4-80A6-7BF79AA304C9Q34031129-3E5F9A82-C564-4541-A379-CB2307FC9112Q34212516-F262DF37-CB0D-401A-A9C4-106F88D26EE3Q34325722-CF0351D3-1C80-4335-85D1-CBB21661F2C7Q34372086-CFD922B6-9DFF-4D9B-8EF4-108E736FA6D0Q34539519-946A888C-A68B-485E-8BA6-D347398E54C0Q34551324-76DA6029-F693-42D9-9E86-C6485E977B58Q34645276-923AF218-C34C-479B-A0F2-8E19CB5E3779Q35023376-DE10A2D1-F04B-46F3-9D9D-1E1B6C77E31AQ35061518-E318E3B2-E68C-48AC-867D-50567F6BA1B5Q35220639-1F983738-2581-465E-932E-4E74CC6ED33CQ35669893-C0E4DA63-B1BD-4FF8-808C-149F962B9B0EQ35923000-268ABE9F-6A03-4A1E-BA79-439E53B2DAFBQ35989943-86683227-5841-4D14-93EA-3EFD91E41EFDQ35996689-43883996-2155-4F1E-B266-1A4535CA1DF7Q36301287-EB865134-F392-401B-A16C-DE49BB0B9AF4Q36777233-99CF072F-FA71-496C-A33D-8D08AF10DC4CQ36976375-F49AAA9D-5BB2-4F8D-AB2D-3BEFAB5F0B4BQ37146672-03FF28F1-0DBE-458A-B8F8-98CDF48E84AFQ37536148-19C330CB-DC3F-4D7C-A247-06F8C9E61C4BQ37552008-59429320-7493-4C2F-BB87-531E9AAAF5CAQ37615538-BD6ED6DA-DB07-4309-A7C4-F181F14F2FE7Q37623809-DD4AEC17-69D5-4344-9833-002169FD429EQ37946701-182367BA-D086-4448-B476-2900C92ED17DQ37970604-C19085D3-D37F-477C-8D82-58F04D13C2D7Q37995195-18F060B1-46D3-4DD9-A8E2-4B1B4365A456Q38000078-198B480E-45B1-4E3B-BB1D-B680573A03A3Q38031989-B0AA2EFA-22BA-4EA2-9E3F-D960CCB41C82Q38037600-30051A74-ACA6-4939-84C0-EE124B0545EAQ38043509-F778296C-3139-4732-BF86-9058190CBD17Q38048281-30044FC8-4E84-4B5A-AA1F-589BE22B18A6Q38059253-AC3B74FD-8B8F-45A3-86A8-53337FB60743
P2860
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Thalidomide for previously unt ...... 6 randomized clinical trials.
@ast
Thalidomide for previously unt ...... 6 randomized clinical trials.
@en
type
label
Thalidomide for previously unt ...... 6 randomized clinical trials.
@ast
Thalidomide for previously unt ...... 6 randomized clinical trials.
@en
prefLabel
Thalidomide for previously unt ...... 6 randomized clinical trials.
@ast
Thalidomide for previously unt ...... 6 randomized clinical trials.
@en
P2093
P50
P1433
P1476
Thalidomide for previously unt ...... 6 randomized clinical trials.
@en
P2093
Anders Waage
European Myeloma Network
Fabian Termorshuizen
Hemato-Oncologie voor Volwassenen Nederland
Ingemar Turesson
Intergroupe Francophone du Myélome
Italian Multiple Myeloma Network
Jean-Yves Mary
Lotfi Benboubker
Martijn Schaafsma
P304
P356
10.1182/BLOOD-2011-03-341669
P407
P50
P577
2011-06-13T00:00:00Z